Evaluation of RLY5016 in Heart Failure Patients (PEARL-HF)

This study has been completed.
Sponsor:
Collaborator:
Medpace, Inc.
Information provided by (Responsible Party):
Relypsa, Inc.
ClinicalTrials.gov Identifier:
NCT00868439
First received: March 23, 2009
Last updated: May 20, 2013
Last verified: May 2013

March 23, 2009
May 20, 2013
April 2009
November 2009   (final data collection date for primary outcome measure)
Change from baseline in serum potassium [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00868439 on ClinicalTrials.gov Archive Site
Safety and tolerability [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Evaluation of RLY5016 in Heart Failure Patients
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients

The purpose of this study is to assess the effects of RLY5016 on serum potassium in heart failure patients. This study will also assess the safety and tolerability of RLY5016 in heart failure patients.

Double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study in up to 270 congestive heart failure patients. Depending on the outcome from the initial cohort of 100 patients (Part 1), a second cohort of 170 patients may be enrolled (Part 2).

Part 1:

One hundred eligible patients will be randomly assigned to receive RLY5016 (30 g/day) or placebo for 28 days. All patients will also receive spironolactone; the initial spironolactone dose is 25 mg daily and will be increased to 50 mg daily for patients who have a serum potassium ≤ 5.1 mEq/L on treatment Day 14. Study visits will be scheduled for treatment Days 3, 7, 14, 17, 21 and 28.

A safety follow-up contact will be made 7 days after administration of last dose of study drug.

An interim analysis will be conducted after data from Part 1 are available.

Part 2:

One hundred seventy eligible patients will be randomly assigned to one of two RLY5016 treatment groups (15 or 60 g/day) or placebo for 28 days. All patients will also receive spironolactone for 28 days; the initial spironolactone dose is 25 mg daily and will be increased to 50 mg daily for patients who have a serum potassium ≤ 5.1 mEq/L on treatment Day 14. Study visits will be scheduled for treatment Days 3, 7, 14, 17, 21 and 28.

A safety follow-up contact will be made 7 days after administration of last dose of study drug.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Hyperkalemia
  • Heart Failure
  • Drug: Spironolactone + RLY5016
    Active investigational drug
  • Drug: Spironolactone + Placebo
    Placebo
  • Active Comparator: RLY5016
    Intervention: Drug: Spironolactone + RLY5016
  • Placebo Comparator: Placebo
    Intervention: Drug: Spironolactone + Placebo
Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. Epub 2011 Jan 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
105
December 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Heart failure patients clinically indicated to receive spironolactone therapy, with serum potassium levels of 4.3 - 5.1 mEq/L AND chronic kidney disease (GFR <60 mL/min) OR documented history of hyperkalemia within the last 6 months
  • Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before study drug administration, during the study, and for one month after study completion
  • Male patients and/or their female partners of child-bearing potential must use a highly effective form of contraception during the study and for 3 months after study completion
  • Must sign informed consent document

Exclusion Criteria:

  • History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery
  • Uncorrected hemodynamically significant primary valvular disease, known obstructive or restrictive cardiomyopathy, uncontrolled or hemodynamically unstable arrhythmia
  • Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic), or major surgery including thoracic and cardiac, within 3 months prior to baseline or anticipated need during study participation
  • Heart transplant recipient, or anticipated need for transplant during study participation
  • Any of the following events having occurred within 3 months prior to baseline: unstable angina as judged by the Investigator, unresolved acute coronary syndrome, transient ischemic attack or stroke
  • Current dialysis patient, or anticipated need for dialysis during study participation
  • Prior kidney transplant, or anticipated need for transplant during study participation
  • Metastatic, late-stage or end-stage cancer with < 12 months life expectancy
  • History of alcoholism or drug/chemical abuse within 1 year
  • QTcB interval > 500 msec (Bazett's correction formula)
  • Sustained systolic blood pressure > 170 or < 90 mmHg
  • Liver enzymes (ALT, AST) > 3 times upper limit of normal
  • Use of oral cardiac medications (including loop and thiazide diuretics) that have not been stable for at least 21 days prior to baseline and are not anticipated to remain stable during study participation
  • Use of any IV cardiac medications within 21 days prior to baseline, or their anticipated need during study participation.
  • Current use of polymer-based drugs (e.g. Renagel, Kayexalate, Welchol, Colestid), other phosphate binders or potassium binders, calcium supplements, antacids (eg TUMS, Maalox), or their anticipated need during study participation
  • Use of aldosterone antagonist in the last 30 days prior to baseline, unless was discontinued due to hyperkalemia
  • Use of potassium sparing medication and/or potassium supplements in the last 30 days prior to baseline
  • Use of any investigational medication, 30 days or 5 half-lives whichever is longer, prior to baseline
  • Patients who have taken investigational product in this study, or a previous RLY5016 study
  • Inability to consume the study medication, or, in the opinion of the Investigator, inability to comply with the protocol
  • In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, serious intercurrent illness, or extenuating circumstance occurring or persisting, within 30 days prior to baseline, that would significantly decrease study compliance or jeopardize the safety of the patient or affect the validity of the trial results
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Czech Republic,   Georgia,   Germany,   Poland,   Russian Federation,   Ukraine
 
NCT00868439
RLY5016-202
No
Relypsa, Inc.
Relypsa, Inc.
Medpace, Inc.
Study Director: Yuri Stasiv, Phd Relypsa, Inc.
Relypsa, Inc.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP